Participate in Research at CU Anschutz

Adult

Inclusion Criteria: 1. Diagnosis of hypoparathyroidism. 2. Patients with previous PTH-treatment experience. 3. Serum albumin-adjusted calcium level ≥7.8 mg/dL and 25(OH) vitamin D in the normal range within 2 weeks before first dose. 4. Male or female at least 18 years of age. 5. Body mass index (BMI) 17 – 40 kg/m2. 6. Be willing and able to give written informed consent by signing an Institutional Review Board (IRB)-approved Informed Consent Form (ICF). Exclusion Criteria: 1. Diagnosis of pseudohypoparathyroidism. 2. Currently enrolled in an investigational drug or device study or has used an investigational drug or device within 30 days or 5 half-lives (whichever is longer) of Day 1. 3. Severe renal impairment (estimated glomerular filtration rate <30 mL/min/1.73m2). 4. Increased risk for osteosarcoma, such as those with Paget's disease of bone or unexplained elevations of alkaline phosphatase, hereditary disorders predisposing to osteosarcoma, or with a prior history of substantial external beam or implant radiation therapy involving the skeleton. 5. Active malignancy within past 2 years excluding successfully resected thyroid carcinoma and non-melanoma skin cancer. 6. Severe or decompensated cardiac disease within 26 weeks, including but not limited to class IV or Stage D heart failure, unstable angina, myocardial infarction or uncontrolled arrhythmias. 7. Pregnant or lactating females, or females intending to become pregnant. 8. Known allergy and/or sensitivity to palopegteriparatide or its excipients or prior PTH therapy. Given the expanded access nature of this program, exemptions may be granted at the discretion of the Sponsor.